Temp reimb extension for antivirals including Tamiflu ends
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.07.16 05:57:26
가나다라
0
Temporarily granted due to concerns over COVID-19 and flu twindemic… High-risk groups were granted reimb coverage without testing
22-month reimb extension measure completed with the Korea Disease Control and Prevention Agency lifting the flu pandemic warning
The limited reimbursement extension granted to antiviral drugs used for influenza such as Tamiflu has ended after 22 months.
The program, which was introduced as a measure to prepare for the simultaneous spread of the COVID-19 and influenza pandemic, came to an end with the recent lifting of the flu pandemic warning. Now that the COVID-19 pandemic has subsided, the old reimbursement standard will be applied in the future in normal circumstances.
According to the Health Insurance Review and Assessment Service (HIRA), the limited health insurance reimbursement coverage granted to influenza antiviral drugs, which had been in effect since September 13, 2022, ended on the 12th.
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)